Cocrystal Pharma, Inc.

COCP Nasdaq SEC CIK 1412486
Follow Cocrystal Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $105K
Net income −$3.4M −68.1% vs same quarter last year
EPS, diluted −$0.20 −5.3% vs same quarter last year
Operating cash flow −$2.3M −68.6% vs same quarter last year
Revenue by quarter
$225K
$105K
$105K
Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$75M−$50M−$25M$0$25MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$8.8M
FY24-−$17.5M
FY23-−$18M
FY22-−$38.8M
FY21-−$14.2M
FY20$2M−$9.6M
FY19$6.6M−$48.2M
FY18-−$49M
FY17-−$613K
FY16-−$74.9M
FY15-−$50.1M
FY14-−$99K
FY13-−$3.9M
FY12-−$8M
FY11$12.7M−$5.5M
MarginsShare of revenue
  • Operating margin
  • Net margin
−800%−600%−400%−200%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21--
FY20−476%−479%
FY19−737.4%−733.8%
FY18--
FY17--
FY16--
FY15--
FY14--
FY13--
FY12--
FY11−30.6%−42.9%
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$8.2M
FY24−$16.5M
FY23−$14.8M
FY22−$21.5M
FY21−$12.8M
FY20−$10.1M
FY19−$1.7M
FY18−$8.3M
FY17−$6.9M
FY16−$14.7M
FY15−$10.7M
FY14−$6M
FY13−$3.7M
FY12−$1.7M
FY11−$996.4K
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Cocrystal Pharma
  • Healthcare median
−800%−600%−400%−200%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCocrystal PharmaHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.9%
FY20−479%−62.2%
FY19−733.8%−46.3%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11−42.9%−27.9%